Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor

Michael Maes, Luisella Bocchio Chiavetto, Stefano Bignotti, Giani Jean Battisa Tura, Rosaria Pioli, Francesco Boin, Gunter Kenis, Eugene Bosmans, Raf De Jongh, Carlo A. Altamura

Research output: Contribution to journalArticle

Abstract

There is now evidence that schizophrenia may be accompanied by an activation of the monocytic and T-helper-2 (Th-2) arms of cell-mediated immunity (CMI) and by various alterations in the Th-1 arm of CMI. There is also evidence that repeated administration of typical and atypical antipsychotics may result in negative immunomodulatory effects. This study was carried out to examine (1) the serum concentrations of interleukin-8 (IL-8), IL-10, the soluble CD8 (sCD8) and the leukemia inhibitory factor receptor (LIF-R) in nonresponders to treatment with typical neuroleptics as compared with normal volunteers and responders to treatment; and (2) the effects of atypical antipsychotics on the above immune variables. The latter were determined in 17 nonresponders to treatment with neuroleptics and in seven normal volunteers and 14 schizophrenic patients who had a good response to treatment with antipsychotic agents. The nonresponders had repeated measurements of the immune variables before, and 2 and 4months after treatment with clozapine or risperidone. Serum IL-8 and IL-10 were significantly higher in schizophrenic patients than in normal controls. The serum concentrations of the sCD8 were significantly increased 2months, but not 4months, after starting treatment with atypical antipsychotics. Serum LIF-R concentrations were significantly increased 2 and 4months after starting treatment with atypical antipsychotics. It is concluded that: (1) schizophrenia is characterized by an activation of both pro-inflammatory and anti-inflammatory aspects of cell-mediated immunity; (2) prolonged treatment with atypical antipsychotics may increase the anti-inflammatory capacity of the serum in schizophrenic patients by increasing serum LIF-R concentrations; and (3) short-term treatment with clozapine may induce signs of immune activation which disappear upon prolonged treatment.

Original languageEnglish (US)
Pages (from-to)281-291
Number of pages11
JournalSchizophrenia Research
Volume54
Issue number3
DOIs
StatePublished - Apr 1 2002
Externally publishedYes

Fingerprint

OSM-LIF Receptors
Clozapine
Interleukin-8
Interleukin-10
Antipsychotic Agents
Serum
Cellular Immunity
Therapeutics
Schizophrenia
Healthy Volunteers
Anti-Inflammatory Agents
Th2 Cells
Risperidone

Keywords

  • Clozapine
  • Cytokines
  • Interleukin-10
  • Interleukin-8
  • Neuroleptics
  • Schizophrenia
  • Treatment resistance

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. / Maes, Michael; Bocchio Chiavetto, Luisella; Bignotti, Stefano; Battisa Tura, Giani Jean; Pioli, Rosaria; Boin, Francesco; Kenis, Gunter; Bosmans, Eugene; De Jongh, Raf; Altamura, Carlo A.

In: Schizophrenia Research, Vol. 54, No. 3, 01.04.2002, p. 281-291.

Research output: Contribution to journalArticle

Maes, Michael ; Bocchio Chiavetto, Luisella ; Bignotti, Stefano ; Battisa Tura, Giani Jean ; Pioli, Rosaria ; Boin, Francesco ; Kenis, Gunter ; Bosmans, Eugene ; De Jongh, Raf ; Altamura, Carlo A. / Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. In: Schizophrenia Research. 2002 ; Vol. 54, No. 3. pp. 281-291.
@article{b30f5ab15e4949d3b87d289626cef656,
title = "Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor",
abstract = "There is now evidence that schizophrenia may be accompanied by an activation of the monocytic and T-helper-2 (Th-2) arms of cell-mediated immunity (CMI) and by various alterations in the Th-1 arm of CMI. There is also evidence that repeated administration of typical and atypical antipsychotics may result in negative immunomodulatory effects. This study was carried out to examine (1) the serum concentrations of interleukin-8 (IL-8), IL-10, the soluble CD8 (sCD8) and the leukemia inhibitory factor receptor (LIF-R) in nonresponders to treatment with typical neuroleptics as compared with normal volunteers and responders to treatment; and (2) the effects of atypical antipsychotics on the above immune variables. The latter were determined in 17 nonresponders to treatment with neuroleptics and in seven normal volunteers and 14 schizophrenic patients who had a good response to treatment with antipsychotic agents. The nonresponders had repeated measurements of the immune variables before, and 2 and 4months after treatment with clozapine or risperidone. Serum IL-8 and IL-10 were significantly higher in schizophrenic patients than in normal controls. The serum concentrations of the sCD8 were significantly increased 2months, but not 4months, after starting treatment with atypical antipsychotics. Serum LIF-R concentrations were significantly increased 2 and 4months after starting treatment with atypical antipsychotics. It is concluded that: (1) schizophrenia is characterized by an activation of both pro-inflammatory and anti-inflammatory aspects of cell-mediated immunity; (2) prolonged treatment with atypical antipsychotics may increase the anti-inflammatory capacity of the serum in schizophrenic patients by increasing serum LIF-R concentrations; and (3) short-term treatment with clozapine may induce signs of immune activation which disappear upon prolonged treatment.",
keywords = "Clozapine, Cytokines, Interleukin-10, Interleukin-8, Neuroleptics, Schizophrenia, Treatment resistance",
author = "Michael Maes and {Bocchio Chiavetto}, Luisella and Stefano Bignotti and {Battisa Tura}, {Giani Jean} and Rosaria Pioli and Francesco Boin and Gunter Kenis and Eugene Bosmans and {De Jongh}, Raf and Altamura, {Carlo A.}",
year = "2002",
month = "4",
day = "1",
doi = "10.1016/S0920-9964(00)00094-3",
language = "English (US)",
volume = "54",
pages = "281--291",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor

AU - Maes, Michael

AU - Bocchio Chiavetto, Luisella

AU - Bignotti, Stefano

AU - Battisa Tura, Giani Jean

AU - Pioli, Rosaria

AU - Boin, Francesco

AU - Kenis, Gunter

AU - Bosmans, Eugene

AU - De Jongh, Raf

AU - Altamura, Carlo A.

PY - 2002/4/1

Y1 - 2002/4/1

N2 - There is now evidence that schizophrenia may be accompanied by an activation of the monocytic and T-helper-2 (Th-2) arms of cell-mediated immunity (CMI) and by various alterations in the Th-1 arm of CMI. There is also evidence that repeated administration of typical and atypical antipsychotics may result in negative immunomodulatory effects. This study was carried out to examine (1) the serum concentrations of interleukin-8 (IL-8), IL-10, the soluble CD8 (sCD8) and the leukemia inhibitory factor receptor (LIF-R) in nonresponders to treatment with typical neuroleptics as compared with normal volunteers and responders to treatment; and (2) the effects of atypical antipsychotics on the above immune variables. The latter were determined in 17 nonresponders to treatment with neuroleptics and in seven normal volunteers and 14 schizophrenic patients who had a good response to treatment with antipsychotic agents. The nonresponders had repeated measurements of the immune variables before, and 2 and 4months after treatment with clozapine or risperidone. Serum IL-8 and IL-10 were significantly higher in schizophrenic patients than in normal controls. The serum concentrations of the sCD8 were significantly increased 2months, but not 4months, after starting treatment with atypical antipsychotics. Serum LIF-R concentrations were significantly increased 2 and 4months after starting treatment with atypical antipsychotics. It is concluded that: (1) schizophrenia is characterized by an activation of both pro-inflammatory and anti-inflammatory aspects of cell-mediated immunity; (2) prolonged treatment with atypical antipsychotics may increase the anti-inflammatory capacity of the serum in schizophrenic patients by increasing serum LIF-R concentrations; and (3) short-term treatment with clozapine may induce signs of immune activation which disappear upon prolonged treatment.

AB - There is now evidence that schizophrenia may be accompanied by an activation of the monocytic and T-helper-2 (Th-2) arms of cell-mediated immunity (CMI) and by various alterations in the Th-1 arm of CMI. There is also evidence that repeated administration of typical and atypical antipsychotics may result in negative immunomodulatory effects. This study was carried out to examine (1) the serum concentrations of interleukin-8 (IL-8), IL-10, the soluble CD8 (sCD8) and the leukemia inhibitory factor receptor (LIF-R) in nonresponders to treatment with typical neuroleptics as compared with normal volunteers and responders to treatment; and (2) the effects of atypical antipsychotics on the above immune variables. The latter were determined in 17 nonresponders to treatment with neuroleptics and in seven normal volunteers and 14 schizophrenic patients who had a good response to treatment with antipsychotic agents. The nonresponders had repeated measurements of the immune variables before, and 2 and 4months after treatment with clozapine or risperidone. Serum IL-8 and IL-10 were significantly higher in schizophrenic patients than in normal controls. The serum concentrations of the sCD8 were significantly increased 2months, but not 4months, after starting treatment with atypical antipsychotics. Serum LIF-R concentrations were significantly increased 2 and 4months after starting treatment with atypical antipsychotics. It is concluded that: (1) schizophrenia is characterized by an activation of both pro-inflammatory and anti-inflammatory aspects of cell-mediated immunity; (2) prolonged treatment with atypical antipsychotics may increase the anti-inflammatory capacity of the serum in schizophrenic patients by increasing serum LIF-R concentrations; and (3) short-term treatment with clozapine may induce signs of immune activation which disappear upon prolonged treatment.

KW - Clozapine

KW - Cytokines

KW - Interleukin-10

KW - Interleukin-8

KW - Neuroleptics

KW - Schizophrenia

KW - Treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=0036535826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036535826&partnerID=8YFLogxK

U2 - 10.1016/S0920-9964(00)00094-3

DO - 10.1016/S0920-9964(00)00094-3

M3 - Article

VL - 54

SP - 281

EP - 291

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 3

ER -